VIGABATRIN
Manufacturer: Lundbeck Pharmaceuticals LLC
Score: 144.0
Vigabatrin is an oral antiepileptic drug used for the treatment of refractory complex partial seizures as adjunctive therapy in patients 2 years of age and older, and as monotherapy for infantile spasms in pediatric patients 1 month to 2 years of age. The drug works by irreversibly inhibiting the enzyme gamma-aminobutyric acid transaminase (GABA-T), leading to increased levels of the inhibitory neurotransmitter GABA in the central nervous system. However, vigabatrin can cause permanent vision loss, and its use requires careful consideration of the benefits and risks. The recommended dosage varies based on age, weight, and indication, and dose adjustments are necessary for patients with renal impairment.
Vigabatrin can cause permanent vision loss, including bilateral concentric visual field constriction and decreased visual acuity
Dose adjustments are necessary for patients with renal impairment, with decreases of 25% for mild impairment, 50% for moderate impairment, and 75% for severe impairment
1000 mg/day (500 mg twice daily), increased weekly by 500 mg increments to a maximum of 3000 mg/day (1500 mg twice daily)
Based on body weight, administered as two divided doses
Not applicable
50 mg/kg/day (25 mg/kg twice daily), increased every 3 days by 25 mg/kg/day to 50 mg/kg/day increments to a maximum of 150 mg/kg/day (75 mg/kg twice daily)